Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure

E-ISSN： 1875-533x|24|34|3813-3827

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.24, Iss.34, 2017-11, pp. : 3813-3827

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination therapy with aspirin and clopidogrel is as effective as warfarin in preventing thromboembolic complications in nonvalvular atrial fibrillation

Inpharma, Vol. 1, Iss. 1449, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Anticoagulants, renal failure and atrial fibrillation

By Genovesi Simonetta

Expert Opinion on Drug Safety, Vol. 12, Iss. 1, 2013-01 ,pp. : 1-3

Informa Healthcare

Access to resources Recommend Favorite

More light at the end of the tunnel – apixaban in atrial fibrillation

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 8, 2012-08 ,pp. : 1235-1239

Informa Healthcare

Access to resources Recommend Favorite

New Advances in Atrial Fibrillation Management: The Role of Apixaban

Current Drug Targets, Vol. 19, Iss. 6, 2018-04 ,pp. : 585-592

Bentham Science Publishers

Access to resources Recommend Favorite

Prognostic Value of INR Fluctuations during Anticoagulant Therapy in Patients with Atrial Fibrillation and a High Thromboembolic Risk

Heart Drug, Vol. 4, Iss. 2, 2004-05 ,pp. : 80-86

Karger

Access to resources Recommend Favorite